Its also important to remember that GLP-1 treatment is a long-term commitment, as most people stay on these medications for an extended period
Overall, these findings are expected to guide future drug design approaches
Newer medications in development, including retatrutide (a triple GIP/GLP-1/glucagon agonist) and amycretin, show promise for improving the fat-to-lean mass ratio during weight loss
The most common side effects are gastrointestinalnausea, vomiting, diarrhea, constipation, and a sense of early fullnesslargely due to delayed gastric emptying and central appetite suppression
Diabetes resolved or dramatically improved Weight regain will likely reverse these improvements
The protective effect of carnitine in human diphtheric myocarditis